QIAGEN Expands QIAcuity Digital PCR Ecosystem with New Gene Expression Assays, High-Multiplex Capabilities, and Workflow Automation
Key Insights
QIAGEN announced new additions to its QIAcuity digital PCR ecosystem, including planned gene expression assays for human, mouse, and rat research applications launching later in 2026.
The new QIAcuity OneStep High Multiplex Probe PCR Kit will enable analysis of up to 12 RNA targets in a single reaction, reducing sample consumption and workflow complexity.
QIAcuity Software 3.5, scheduled for release later this month, introduces automated analysis templates and reporting to standardize data interpretation in regulated workflows.
QIAGEN N.V. (search) (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced significant expansions to its QIAcuity digital PCR (dPCR) ecosystem, targeting one of the largest application areas in molecular biology — gene expression analysis — while simultaneously strengthening workflow automation and Cell and Gene Therapy quality control offerings.
"Gene expression represents one of the largest application areas in molecular biology and a significant opportunity for digital PCR," said Thierry Bernard, CEO of QIAGEN. "By expanding the QIAcuity ecosystem with new assays, enhanced multiplexing capabilities and workflow solutions, we are helping customers apply digital PCR to a broader range of research and biopharma applications."
New Gene Expression Solutions for dPCR
Later in 2026, QIAGEN plans to launch new QIAcuity Gene Expression Assays designed to support gene expression analysis across human, mouse, and rat research applications. The company also intends to introduce the QIAcuity OneStep High Multiplex Probe PCR Kit, which enables analysis of up to 12 RNA targets in a single reaction. This high-multiplex capability is designed to help researchers generate richer biological insights while reducing sample consumption, hands-on time, and workflow complexity.
These new offerings complement QIAGEN's existing GeneGlobe platform, which provides access to more than 10 million predesigned assays as well as custom assay design capabilities for specialized research needs.
Expanded Cell and Gene Therapy Quality Control Portfolio
Building on its established portfolio of dPCR solutions for Cell and Gene Therapy applications, QIAGEN is expanding its residual DNA testing offering to support additional producer cell systems, including Sf9/Baculovirus, Pichia pastoris, Vero, and Mouse. The portfolio also includes the recently launched QIAcuity HEK293 resDNA Sizing Kit, which enables precise measurement of both host-cell DNA concentration and fragment size distribution to support biopharmaceutical development and manufacturing workflows.
Automated Analysis and Reporting with QIAcuity Software 3.5
Scheduled for release later this month, QIAcuity Software 3.5 introduces advanced analysis templates and automated reporting capabilities that enable users to define analysis and reporting parameters before a run begins. The software helps laboratories automate and standardize data interpretation and reporting through predefined analysis and reporting templates. By automatically applying analysis parameters and generating reports after run completion, laboratories can reduce manual review steps while improving traceability, consistency, and operational efficiency, particularly in larger-scale and regulated workflows.
Expanded Laboratory Automation through Hamilton Integration
In addition to the software enhancements, customers can build on QIAGEN's collaboration with Hamilton to automate QIAcuity dPCR nanoplate setup and handling workflows, including sample preparation, nanoplate filling, and sealing. Integration with robotic systems enables fully automated workflows from assay setup through data analysis, helping high-throughput laboratories increase productivity while minimizing risks associated with manual handling.
Growing Adoption Across Research and Biopharma
QIAcuity adoption continues to grow across academia, biopharma, and clinical research, with over 3,200 cumulative placements worldwide since launch. More than 400 customers now operate multiple QIAcuity instruments, while over 1,100 scientific publications reference the platform. The continued expansion of the QIAcuity ecosystem reflects QIAGEN's strategy to support customers throughout the transition from qPCR to dPCR and toward increasingly scalable, automated, and standardized dPCR workflows.
Additional details on QIAGEN's QIAcuity dPCR strategy, technology roadmap, and growth opportunities will be discussed during the upcoming QIAcuity Deep Dive event on Monday, June 15, 2026. The event will be webcast and available to investors, analysts, and other interested stakeholders.